Navigation Links
Xenon Announces Appointment of VP, Discovery Research
Date:2/6/2008

VANCOUVER, Canada, Feb. 6 /PRNewswire/ -- Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has appointed Charles J. Cohen as Vice President, Discovery Research.

"We are delighted to welcome Charlie to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "Charlie brings a unique combination of drug discovery experience and leadership including in areas that are highly relevant to Xenon such as pain. With a drug candidate for pain currently in clinical trials, and a backup compound expected to follow, we are certain that Charlie's background will be of great benefit to Xenon. In addition to his experience in the pain area, Charlie brings broad and diverse expertise which will be applicable to our multiple discovery and pre-clinical programs."

Dr. Cohen has spent the past approximately 25 years in the pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals, Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and has published widely in the area of pain and more broadly in cellular neuroscience and neurology. Dr. Cohen received his PhD in Biophysics and Theoretical Biology from the University of Chicago.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of Pain, Diabetes/Obesity, Anemia and Iron Overload. Xenon has partnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical Company Ltd. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially
'/>"/>

SOURCE Xenon Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
2. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
3. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
4. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
5. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
6. CardioTech Announces Conference Call on February 12 at 2:30 PM Eastern for Third Quarter of Fiscal 2008
7. NeoStem Announces NY State License for Adult Stem Cell Collection
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
10. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... (PRWEB) March 31, 2015 Eastern ... schools for online bachelor’s of criminal justice degree ... connecting people to inspiring ideas and high quality ... e-mail to the University. We are confident that ... , This is the site’s first “Students ...
(Date:3/31/2015)... 2015 Pittcon 2015, the 66th Conference ... on March 12, in New Orleans with an economic ... estimated by the New Orleans Convention and Visitor's Bureau. ... and exhibitor personnel. Those who attended Pittcon for ... For the third year, the co-location of Food Labs ...
(Date:3/31/2015)...  Bayer HealthCare (Bayer) has expanded its collaboration ... Technology (MIT) and Harvard University to include cardiovascular ... new part of the alliance is to leverage ... cardiovascular therapies. "We are excited to ... the area of cardiovascular genomics to discover genes ...
(Date:3/31/2015)... SALT LAKE CITY , March 31, 2015 /PRNewswire-USNewswire/ ... second milestone with the selection of ten proposals ... The MCRI is the first patient-led, scientifically validated ... patients. Stage 2 of the MCRI ... "After careful review of a large number of ...
Breaking Biology Technology:EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2Pittcon 2015 Hits the Big Easy in a Big Way 2Pittcon 2015 Hits the Big Easy in a Big Way 3Pittcon 2015 Hits the Big Easy in a Big Way 4Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2
... (NYSE: SGP ) will provide a live ... chairman and chief executive officer, followed,by a question-and-answer ... on Jan. 3, 2008, at approximately 8:45 a.m. ... presentation., Included in Mr. Hassan,s comments will ...
... Fla., Dec. 27 Phlo Corporation,(Pink Sheets: PHLC) ("Phlo") ... completed the initial shipment of its vitality beverage,product, AQISS(TM), ... in the,metropolitan New York City area, including Manhattan, Brooklyn, ... launched in a key account base, some of which ...
... Dec. 27 /Xinhua-PRNewswire/ -- Asymchem, one of China,s,leading ... plans in China. Apart from new plants and ... heavily in training and form strategic alliances,in the ... I. Quality Facilities: New cGMP Pilot Plant ...
Cached Biology Technology:Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference 2Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base 2Three Steps to Boost Asymchem's Investment in China 2Three Steps to Boost Asymchem's Investment in China 3Three Steps to Boost Asymchem's Investment in China 4
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... , BIRMINGHAM, Ala. A new study at the University ... and abdominal obesity, which has been linked to an increased ... that in a sample of young adults during a 15-year ... gained weight at a faster rate than others in the ...
... -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology ... disorders, today announced that its investigational first-in-class Neurally ... COL-144), a selective 5-HT1F receptor agonist, was effective ... as documented in a Phase IIb study. Results ...
... the 2010 International Conference on Emerging Infectious Diseases (ICEID), ... Regency, Atlanta, Georgia. The meeting is being organized ... the American Society for Microbiology, the Council of State ... and the World Health Organization. The International Conference ...
Cached Biology News:UAB study confirms link between depression, abdominal obesity 2CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks 22010 International Conference on Emerging Infectious Diseases 2
... in both reduced and non-reduced forms. It does ... human Factor XII. Factor XIII is a Beta-globulin ... subunits. Factor XIII-A is the catalytic subunit and ... is present in plasma as an Alpha2Beta2 heterodimer ...
... Phosphatase 2 (LPP2) fractionated ... solution Solution in ... 0.08% sodium azide. unique ... human LPP2 protein. The ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... mM NaCl, 10 mM sodium ... glycerol, pH 7.5. Recognizes the ... kinase 2 (MAPKAPK-2) protein phosphorylated ...
Biology Products: